131
0.00%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About TMS Co
Its shares trade on Tokyo Stock Exchange under the ticker 4891.T. It has been listed since 22 November 2022. In the fiscal year to 28 February 2022, it reported revenue of ¥1.95bn and net income of ¥1.08bn. At that date it held total assets of ¥2.74bn and shareholders' equity of ¥2.45bn.
TMS Co., Ltd. engages in the research and development of pharmaceutical products and medical devices. The company is headquartered in Fuchu-Shi, Tokyo-To. The company went IPO on 2022-11-22. The firm conducts research and development of drug candidate substances based on the research and development results of academia and other research institutions. The current pipeline consists of drug candidates targeting soluble epoxide hydrolase (sEH), one of the enzymes in the human body. sEH inhibition has been shown to provide anti-inflammatory effects and the Company is developing sEH inhibitors for a variety of inflammatory diseases. The lead pipeline, TMS-007, has an anti-inflammatory effect by inhibiting sEH and a thrombolytic effect by acting on plasminogen, and will be clinically developed for acute cerebral infarction. TMS-008, a follow-on product in the pipeline, is being developed for various inflammatory diseases and is currently undergoing pre-clinical studies.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 22 Nov 2022
- Employees
- 14
- Website
- tms-japan.co.jp ↗
Leadership
Pay as last reported
- Mr. Keiji HasumiChairman of the Board, since 2005
- Mr. Takuro WakabayashiPresident, Representative Director, since 2011
- Mr. Noriaki InamuraDirector
- Mr. Tsuyoshi ItoDirector
- Ms. Reiko NamikawaIndependent Director
- Mr. Ken TakanashiIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- TMS Co Ltd employs 14 full-time employees focused on biotechnology research and development.
- TMS-007 targets acute cerebral infarction with dual anti-inflammatory and thrombolytic effects.
- TMS-008 is in pre-clinical studies for various inflammatory diseases based on sEH inhibition.
Weaknesses
- TMS Co Ltd has only 14 employees which may limit research capacity.
- The company's IPO occurred in November 2022 with limited market presence.
- TMS Co Ltd is headquartered in Fuchu-shi, Tokyo-To, a location with less industry concentration.
Opportunities
- The sEH inhibition market shows potential for anti-inflammatory drug development.
- TMS-007's clinical development for acute cerebral infarction could address unmet medical needs.
- TMS-008's pre-clinical studies may lead to new treatments for inflammatory diseases.
Threats
- TMS Co Ltd faces competition from established biotechnology firms in Japan.
- The biotechnology sector requires significant capital investment for clinical trials.
- Regulatory approval processes for new drugs can delay market entry.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.